Phase I clinical study of a WT1-W10 peptide immunotherapy combined with standard treatment against diffuse midline glioma (WT1-TR-DMG).

Trial Profile

Phase I clinical study of a WT1-W10 peptide immunotherapy combined with standard treatment against diffuse midline glioma (WT1-TR-DMG).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2017

At a glance

  • Drugs WT1-W10 peptide vaccine (Primary) ; Bevacizumab; Temozolomide
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions
  • Acronyms WT1-TR-DMG
  • Most Recent Events

    • 07 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top